NASDAQ: EQ
Equillium Inc Stock Forecast, Predictions & Price Target

Analyst price target for EQ

Based on 1 analyst offering 12 month price targets for Equillium Inc

Min Forecast
$1.00+138.1%
Avg Forecast
$1.00+138.1%
Max Forecast
$1.00+138.1%

Should I buy or sell EQ stock?

Based on 1 analyst offering ratings for Equillium Inc.

Hold
Strong Buy
0 analysts 0%
Buy
0 analysts 0%
Hold
1 analysts 100%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%

Be the first to know when Wall Street analysts revise their EQ stock forecasts and price targets.

EQ stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2025-03-28

1 of 1

Forecast return on equity

Is EQ forecast to generate an efficient return?

Company
-80.33%
Industry
142.9%
Market
80.27%
EQ's Return on Equity is... subscribe to Premium to read more.
Forecast High Return on Equity Forecast

Forecast return on assets

Is EQ forecast to generate an efficient return on assets?

Company
-59.8%
Industry
35.65%
EQ is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

EQ earnings per share forecast

What is EQ's earnings per share in the next 3 years based on estimates from 2 analysts?

Avg 1 year Forecast
-$0.72
Avg 2 year Forecast
-$1.05
Avg 3 year Forecast
-$0.77

EQ revenue forecast

What is EQ's revenue in the next 3 years based on estimates from 1 analyst?

Avg 1 year Forecast
$15.6M-62.09%
Avg 2 year Forecast
$16.5M-59.8%
Avg 3 year Forecast
$51.7M+25.78%
EQ's revenue is forecast to... subscribe to Premium to read more.
Forecast High Revenue Growth Forecast

EQ revenue growth forecast

How is EQ forecast to perform vs Biotechnology companies and vs the US market?

Company
-43.8%
Industry
64.17%
Market
10.07%
EQ's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Industry Forecast
EQ's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Market Forecast

EQ vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
EQ$0.42$1.00+138.10%Hold
MBRX$1.06$6.00+466.04%Strong Buy
BIVI$0.82N/AN/A
PHGE$0.61$21.00+3,348.28%Buy
BCDA$3.14$25.00+696.18%Buy

Equillium Stock Forecast FAQ

Is Equillium Stock a good buy in 2025, according to Wall Street analysts?

The consensus among 1 Wall Street analyst covering (NASDAQ: EQ) stock is to Hold EQ stock.

Out of 1 analyst, 0 (0%) are recommending EQ as a Strong Buy, 0 (0%) are recommending EQ as a Buy, 1 (100%) are recommending EQ as a Hold, 0 (0%) are recommending EQ as a Sell, and 0 (0%) are recommending EQ as a Strong Sell.

If you're new to stock investing, here's how to buy Equillium stock.

What is EQ's earnings growth forecast for 2025-2027?

(NASDAQ: EQ) Equillium's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 12.96%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 17.59%.

Equillium's earnings in 2025 is -$8,067,000.On average, 2 Wall Street analysts forecast EQ's earnings for 2025 to be -$25,461,084, with the lowest EQ earnings forecast at -$27,775,727, and the highest EQ earnings forecast at -$23,146,440. On average, 1 Wall Street analyst forecast EQ's earnings for 2026 to be -$37,390,402, with the lowest EQ earnings forecast at -$37,390,402, and the highest EQ earnings forecast at -$37,390,402.

In 2027, EQ is forecast to generate -$27,419,628 in earnings, with the lowest earnings forecast at -$27,419,628 and the highest earnings forecast at -$27,419,628.

What is EQ's revenue growth forecast for 2026-2028?

(NASDAQ: EQ) Equillium's forecast annual revenue growth rate of -43.8% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 64.17%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 10.07%.

Equillium's revenue in 2025 is $41,095,000.On average, 1 Wall Street analysts forecast EQ's revenue for 2026 to be $554,802,351, with the lowest EQ revenue forecast at $554,802,351, and the highest EQ revenue forecast at $554,802,351. On average, 1 Wall Street analysts forecast EQ's revenue for 2027 to be $588,275,664, with the lowest EQ revenue forecast at $588,275,664, and the highest EQ revenue forecast at $588,275,664.

In 2028, EQ is forecast to generate $1,840,676,093 in revenue, with the lowest revenue forecast at $1,840,676,093 and the highest revenue forecast at $1,840,676,093.

What is EQ's forecast return on assets (ROA) for 2025-2028?

(NASDAQ: EQ) forecast ROA is -59.8%, which is lower than the forecast US Biotechnology industry average of 35.65%.

What is EQ's Price Target?

According to 1 Wall Street analyst that have issued a 1 year EQ price target, the average EQ price target is $1.00, with the highest EQ stock price forecast at $1.00 and the lowest EQ stock price forecast at $1.00.

The Wall Street analyst predicted that Equillium's share price could reach $1.00 by Mar 28, 2026. The average Equillium stock price prediction forecasts a potential upside of 138.1% from the current EQ share price of $0.42.

What is EQ's Earnings Per Share (EPS) forecast for 2025-2027?

(NASDAQ: EQ) Equillium's current Earnings Per Share (EPS) is -$0.23. On average, analysts forecast that EQ's EPS will be -$0.72 for 2025, with the lowest EPS forecast at -$0.78, and the highest EPS forecast at -$0.65. On average, analysts forecast that EQ's EPS will be -$1.05 for 2026, with the lowest EPS forecast at -$1.05, and the highest EPS forecast at -$1.05. In 2027, EQ's EPS is forecast to hit -$0.77 (min: -$0.77, max: -$0.77).

What is EQ's forecast return on equity (ROE) for 2025-2028?

(NASDAQ: EQ) forecast ROE is -80.33%, which is considered weak.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.